Download PDF
Digestive Disease Interventions 2017; 01(02): 115-120
DOI: 10.1055/s-0037-1603961
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA

Balloon-Assisted Transarterial Chemoembolization: A Nascent Strategy for the Treatment of Hepatocellular Carcinoma

Sirish A. Kishore
1   Department of Radiology, Division of Interventional Radiology, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York
,
Wayne Y. Cheng
1   Department of Radiology, Division of Interventional Radiology, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York
,
John B. Smirniotopoulos
1   Department of Radiology, Division of Interventional Radiology, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York
,
David C. Madoff
1   Department of Radiology, Division of Interventional Radiology, New York Presbyterian Hospital-Weill Cornell Medicine, New York, New York
› Author Affiliations
Further Information

Publication History

31 May 2017

02 June 2017

Publication Date:
19 June 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. The majority of newly diagnosed patients are not eligible for curative options, and thus, transarterial therapies such as transarterial chemoembolization (TACE) play a central role in prolonging survival for the majority of patients with liver-confined HCC. Recent developments in microcatheter technology have allowed for increasingly localized intratumoral administration of chemotherapeutic agents as a result of lower profile catheters and occlusion balloon-catheter systems. The purpose of this review is to describe the current state of balloon-assisted transarterial chemoembolization (B-TACE), a nascent transarterial locoregional therapeutic strategy for the treatment of HCC that may confer benefit over conventional TACE (cTACE) in selected patients.

Keywords

hepatocellular carcinoma - TACE - chemoembolization - balloon
 

  • References

  • 1 Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2011; 20 (11) 2362-2368
    CrossrefPubMedGoogle Scholar
  • 2 Lo CM, Ngan H, Tso WK. , et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (05) 1164-1171
    CrossrefPubMedGoogle Scholar
  • 3 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37 (02) 429-442
    CrossrefPubMedGoogle Scholar
  • 4 Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148 (02) 397-401
    CrossrefPubMedGoogle Scholar
  • 5 Sasaki Y, Imaoka S, Kasugai H. , et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60 (06) 1194-1203
    CrossrefPubMedGoogle Scholar
  • 6 Miyayama S, Matsui O, Yamashiro M. , et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 2007; 18 (03) 365-376
    CrossrefPubMedGoogle Scholar
  • 7 Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc Intervent Radiol 2013; 36 (03) 706-713
    CrossrefPubMedGoogle Scholar
  • 8 Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30 (05) 969-977
    PubMedGoogle Scholar
  • 9 Kim BK, Kim SU, Kim KA. , et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol 2015; 62 (06) 1304-1310
    CrossrefPubMedGoogle Scholar
  • 10 Miyayama S, Mitsui T, Zen Y. , et al. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res 2009; 39 (04) 374-381
    CrossrefPubMedGoogle Scholar
  • 11 Murakami R, Yoshimatsu S, Yamashita Y, Sagara K, Arakawa A, Takahashi M. Transcatheter hepatic subsegmental arterial chemoembolization therapy using iodized oil for small hepatocellular carcinomas. Correlation between lipiodol accumulation pattern and local recurrence. Acta Radiol 1994; 35 (06) 576-580
    CrossrefPubMedGoogle Scholar
  • 12 Imai N, Ishigami M, Ishizu Y. , et al. Transarterial chemoembolization for hepatocellular carcinoma: a review of techniques. World J Hepatol 2014; 6 (12) 844-850
    CrossrefPubMedGoogle Scholar
  • 13 Hoshiai S, Mori K, Ishiguro T. , et al. Balloon-assisted chemoembolization using a micro-balloon catheter alongside a microcatheter for a hepatocellular carcinoma with a prominent arterioportal shunt: a case report. Cardiovasc Intervent Radiol 2017; 40 (04) 625-628
    CrossrefPubMedGoogle Scholar
  • 14 Miyayama S, Matsui O, Taki K. , et al. Combined use of an occlusion balloon catheter and a microcatheter for embolization of the unselectable right inferior phrenic artery supplying hepatocellular carcinoma. Cardiovasc Intervent Radiol 2004; 27 (06) 677-681
    CrossrefPubMedGoogle Scholar
  • 15 Matsumoto T, Endo J, Hashida K. , et al. Balloon-occluded transarterial chemoembolization using a 1.8-French tip coaxial microballoon catheter for hepatocellular carcinoma: technical and safety considerations. Minim Invasive Ther Allied Technol 2015; 24 (02) 94-100
    CrossrefPubMedGoogle Scholar
  • 16 Matsumoto T, Endo J, Hashida K. , et al. Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization. Minim Invasive Ther Allied Technol 2016; 25 (01) 22-28
    CrossrefPubMedGoogle Scholar
  • 17 Kakuta A, Shibutani K, Ono S. , et al. Temporal variations in stump pressure and assessment of images obtained from cone-beam computed tomography during balloon-occluded transarterial chemoembolization. Hepatol Res 2016; 46 (05) 468-476
    CrossrefPubMedGoogle Scholar
  • 18 Yoshimatsu R, Yamagami T, Ishikawa M. , et al. Change in imaging findings on angiography-assisted CT during balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2016; 39 (06) 865-874
    CrossrefPubMedGoogle Scholar
  • 19 Asayama Y, Nishie A, Ishigami K. , et al. Hemodynamic changes under balloon occlusion of hepatic artery: predictor of the short-term therapeutic effect of balloon-occluded transcatheter arterial chemolipiodolization using miriplatin for hepatocellular carcinoma. Springerplus 2016; 5: 157
    CrossrefPubMedGoogle Scholar
  • 20 Kawamura Y, Ikeda K, Fujiyama S. , et al. Usefulness and limitations of balloon-occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules. Hepatol Res 2017; 47 (04) 338-346
    CrossrefPubMedGoogle Scholar
  • 21 Ishikawa T, Abe S, Inoue R. , et al. Predictive factor of local recurrence after balloon-occluded TACE with miriplatin (MPT) in hepatocellular carcinoma. PLoS One 2014; 9 (07) e103009
    CrossrefPubMedGoogle Scholar
  • 22 Kudo M, Ueshima K, Kubo S. , et al; Liver Cancer Study Group of Japan. Response evaluation criteria in cancer of the liver (RECICL) (2015 revised version). Hepatol Res 2016; 46 (01) 3-9
    CrossrefPubMedGoogle Scholar
  • 23 Minami Y, Minami T, Chishina H. , et al. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma: a single-center experience. Oncology 2015; 89 (Suppl. 02) 27-32
    CrossrefPubMedGoogle Scholar
  • 24 Maruyama M, Yoshizako T, Nakamura T, Nakamura M, Yoshida R, Kitagaki H. Initial experience with balloon-occluded trans-catheter arterial chemoembolization (B-TACE) for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2016; 39 (03) 359-366
    CrossrefPubMedGoogle Scholar
  • 25 Arai H, Abe T, Takayama H. , et al. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol Res 2015; 45 (06) 663-666
    CrossrefPubMedGoogle Scholar
  • 26 Ogawa M, Takayasu K, Hirayama M. , et al. Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: short-term results. Hepatol Res 2016; 46 (03) E60-E69
    CrossrefPubMedGoogle Scholar
  • 27 Irie T, Kuramochi M, Kamoshida T, Takahashi N. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE. Hepatol Res 2016; 46 (02) 209-214
    CrossrefPubMedGoogle Scholar
  • 28 Golfieri R, Renzulli M, Mosconi C. , et al; Bologna Liver Oncology Group (BLOG). Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension?. J Vasc Interv Radiol 2013; 24 (04) 509-517
    CrossrefPubMedGoogle Scholar